Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1261 | Double-Blind NT-I7 Wiki | 1.00 |
| drug1262 | Double-Blind Placebo Wiki | 1.00 |
| drug3373 | Risankizumab Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014456 | Ulcer NIH | 0.30 |
| D003092 | Colitis NIH | 0.30 |
| D003093 | Colitis, Ulcerative NIH | 0.30 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002583 | Colitis HPO | 0.30 |
| HP:0100279 | Ulcerative colitis HPO | 0.30 |
| HP:0100280 | Crohn's disease HPO | 0.30 |
Navigate: Correlations HPO
There is one clinical trial.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD. Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide. In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
Description: Maximum observed plasma concentration (Cmax) of Midazolam
Measure: Maximum Observed Plasma Concentration (Cmax) of Midazolam Time: Up to 71 DaysDescription: Time to maximum plasma concentration (Tmax) of Midazolam
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Measure: AUC From Time 0 to Infinity (AUCinf) of Midazolam Time: Up to 71 DaysDescription: Terminal phase elimination rate constant (β) for Midazolam
Measure: Terminal Phase Elimination Rate Constant (β) of Midazolam Time: Up to 71 DaysDescription: Terminal phase elimination half-life (t1/2) of Midazolam
Measure: Terminal Phase Elimination Half-Life (t1/2) of Midazolam Time: Up to 71 DaysDescription: Maximum observed plasma concentration (Cmax) of Caffeine
Measure: Maximum Observed Plasma Concentration (Cmax) of Caffeine Time: Up to 71 DaysDescription: Time to maximum plasma concentration (Tmax) of Caffeine
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Measure: AUC From Time 0 to Infinity (AUCinf) of Caffeine Time: Up to 71 DaysDescription: Terminal phase elimination rate constant (β) for Caffeine
Measure: Terminal Phase Elimination Rate Constant (β) of Caffeine Time: Up to 71 DaysDescription: Terminal phase elimination half-life (t1/2) of Caffeine
Measure: Terminal Phase Elimination Half-Life (t1/2) of Caffeine Time: Up to 71 DaysDescription: Maximum observed plasma concentration (Cmax) of Warfarin
Measure: Maximum Observed Plasma Concentration (Cmax) of Warfarin Time: Up to 71 DaysDescription: Time to maximum plasma concentration (Tmax) of Warfarin
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Measure: AUC From Time 0 to Infinity (AUCinf) of Warfarin Time: Up to 71 DaysDescription: Terminal phase elimination rate constant (β) for Warfarin
Measure: Terminal Phase Elimination Rate Constant (β) of Warfarin Time: Up to 71 DaysDescription: Terminal phase elimination half-life (t1/2) of Warfarin
Measure: Terminal Phase Elimination Half-Life (t1/2) of Warfarin Time: Up to 71 DaysDescription: Maximum observed plasma concentration (Cmax) of Omeprazole
Measure: Maximum Observed Plasma Concentration (Cmax) of Omeprazole Time: Up to 71 DaysDescription: Time to maximum plasma concentration (Tmax) of Omeprazole
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Measure: AUC From Time 0 to Infinity (AUCinf) of Omeprazole Time: Up to 71 DaysDescription: Terminal phase elimination rate constant (β) for Omeprazole
Measure: Terminal Phase Elimination Rate Constant (β) of Omeprazole Time: Up to 71 DaysDescription: Terminal phase elimination half-life (t1/2) of Omeprazole
Measure: Terminal Phase Elimination Half-Life (t1/2) of Omeprazole Time: Up to 71 DaysDescription: Maximum observed plasma concentration (Cmax) of Metoprolol
Measure: Maximum Observed Plasma Concentration (Cmax) of Metoprolol Time: Up to 71 DaysDescription: Time to maximum plasma concentration (Tmax) of Metoprolol
Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol Time: Up to 71 DaysDescription: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Measure: AUC From Time 0 to Infinity (AUCinf) of Metoprolol Time: Up to 71 DaysDescription: Terminal phase elimination rate constant (β) for Metoprolol
Measure: Terminal Phase Elimination Rate Constant (β) of Metoprolol Time: Up to 71 DaysDescription: Terminal phase elimination half-life (t1/2) of Metoprolol
Measure: Terminal Phase Elimination Half-Life (t1/2) of Metoprolol Time: Up to 71 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports